Roles of GCK mRNA and GLUT2 in abnormal glucose metabolism among patients with severe chronic hepatitis B

Zhang FenYan; Feng YanMei; Zhu YueKe; Zhang LiJie; Yu HongWei; Li Juan; Fu WanFa; Meng QingHua

doi:10.3969/j.issn.1001-5256.2013.08.014

Issue 8

Aug. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(8): 607-610

PDF( 1400 KB)

Roles of GCK mRNA and GLUT2 in abnormal glucose metabolism among patients with severe chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2013.08.014

Research funding:

Received Date: 2013-02-17
Published Date: 2013-08-20

Abstract

Abstract

Objective To evaluate the expression of glucokinase (GCK) mRNA and glucose transporter-2 (GLUT2) in the liver tissues of patients with severe chronic hepatitis B and to preliminarily investigate their roles in abnormal glucose metabolism among patients with severe chronic hepatitis B.Methods The expression of GCK mRNA in the liver tissues of 10 patients with severe chronic hepatitis B and 10 patients with liver cirrhosis (Child-Turcotte-Pugh grade A) was evaluated by RT-PCR.The expression of GLUT2 in the liver tissues of the above 10 patients with severe chronic hepatitis B and 10 normal controls was evaluated by immunohistochemistry.The t-test was used for mean comparison between groups;the Pearson correlation test was used for correlation analysis.Results The expression level of GCK mRNA in liver tissue was significantly lower in the patients with severe chronic hepatitis B than in those with liver cirrhosis (1.13±0.11 vs 1.44±0.14, P<0.05) .In the patients with severe chronic hepatitis B, the level of GCK mRNA in liver tissue had a positive correlation with the oxidation rate of carbohydrates (r=0.845, P<0.01) but="" it="" had="" no="" correlation="" with="" fasting="" blood="" glucose="" r="0.03," p="">0.05) .The expression of GLUT2 was reduced in the liver tissues of patients with severe chronic hepatitis B, and it was distributed in the hepatic cells around pseudolobuli (nodules) .Conclusion The level of GCK mRNA is closely related to the oxidation of carbohydrates.The decreased expression of GCK mRNA and GLUT2 is one of the mechanisms of abnormal glucose metabolism in patients with severe chronic hepatitis B.
- hepatitis B,
- chronic,
- glucose transporter type 2,
- glucokinase

FullText(HTML)

References(16)

References

[1]YAO GB.Clinical hepatology[M].Shanghai:Shanghai Scientificand Technical Press, 2004:28-30. (in Chinese) 姚光弼.临床肝脏病学[M].上海:上海科学技术出版社, 2004:28-30.

[2]RU QJ, XU S.Current situation of research on prognostic evaluationin liver failure[J].Clin J Integr Tradit West Med Liver, 2010, 20 (6) :377-383. (in Chinese) 茹清静, 徐删.肝衰竭预后评估研究现状[J].中西医结合肝病杂志, 2010, 20 (6) :377-383.

[3]HONG SY, WANG, MS, ZHAO HM.Clinical analysis of hypogly-cemia in patients with sever viral hepatitis[J].Chin Hepatol, 2005, 10 (2) :98-99. (in Chinese) 洪尚游, 万谟彬, 赵汉美.重型病毒性肝炎并发低血糖临床分析[J].肝脏, 2005, 10 (2) :98-99.

[4]YUE JR, LI O, ZHANG LP.Hypoglycemia monitor and nursing in-tervention on chronic and severe hepatitis[J].J Clin Exp Med, 2006, 5 (6) :788-789. (in Chinese) 岳建荣, 李藕, 张丽萍.慢性重型肝炎患者低血糖监测及护理干预[J].临床和实验医学杂志, 2006, 5 (6) :788-789.

[5]TAJIKA M, KATO M, MOHRI H, et al.Prognostic value of energymetabolism in patients with viral liver cirrhosis[J].Nutrition, 2002, 18 (3) :229-234.

[6]YU HW, MENG QH, ZHANG FY.Research on mechanism of hy-poglycemia in patients with severe chronic hepatitis B[J].J ClinHepatol, 2008, 24 (3) :175-178. (in Chinese) 于红卫, 孟庆华, 张汾燕.慢性重型乙型肝炎患者低血糖机制的探讨[J].临床肝胆病杂志, 2008, 24 (3) :175-178.

[7]BECHMANN LP, GASTALDELLI A, VETTER D, et al.Glucoki-nase links Krüppel-like factor 6 to the regulation of hepatic insulinsensitivity in nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (4) :1083-1093.

[8]FANG CL, WU YJ, DING HG, et al.Energy metabolism and sub-strate oxidation in patients with severe chronic hepatits B[J].ChinJ Clin Nutr, 2006, 14 (2) :110-114. (in Chinese) 范春蕾, 武燕京, 丁惠国, 等.慢性重型病毒性肝炎的能量代谢及糖、蛋白质、脂肪氧化[J].中国临床营养杂志, 2006, 14 (2) :110-114.

[9]YU HW, MENG QH, ZHANG FY, et al.Correlation between hypogly-cemia and energy metabolism and insulin-like growth factor-1 in pa-tient with chronic severe hepatitis B[J].Chin J Clin Nutr, 2008, 16 (1) :8-11. (in Chinese) 于红卫, 孟庆华, 张汾燕, 等.慢性重型乙型肝炎患者低血糖与能量代谢、胰岛素样生长因子-1的相关性[J].中国临床营养杂志, 2008, 16 (1) :8-11.

[10]HAO JY, YANG SX.Experimental study of glucokinase in carbohy-drate metabolism of liver cirrhosis[J].Beijing Med J, 2005, 27 (6) :351-353. (in Chinese) 郝建宇, 杨昭徐.葡萄糖激酶在肝硬化糖代谢异常中的实验研究[J].北京医学, 2005, 27 (6) :351-353.

[11]PETER A, STEFAN N, CEGAN A, et al.Hepatic glucokinase ex-pression is associated with lipogenesis and fatty liver in humans[J].J Clin Endocrinol Metab, 2011, 6 (7) :1126-1130.

[12]IM SS, KIM SY, KIM HI.et al.Transcriptional regulation of glu-cose sensors in pancreatic beta cells and liver[J].Curr DiabetesRev, 2006, 2 (1) :11-18.

[13]CUNHA AC, PEREIRA RO, PEREIRA MJ, et al.Long termeffects of over feeding during lactation on insulin secretion-the roleof Glut2[J].J Nutr Biochem, 2009, 20 (6) :435-442.

[14]DONG LZ, LIE SL, XUN J, et al.Effects and mechanism of duo-denal-jejunal bypass and sleeve gastrectomy on GLUT2 and glu-cokinase in diabetic Goto-Kakizaki rats[J].Eur J Med Res, 2012, 17 (15) :186-192.

[15]JUNGERMANN K, KIETZMANN T.Zonation of parenchymal andnonparenchymal metabolism in liver[J].Annu Rev Nutr, 1996, 16:179.

[16]ARDEN C, PETRIE JL, TUDHOPE SJ, et al.Elevated glucose re-presses liver glucokinase and induces its regulatory protein to safe-guard hepatic phosphate homeostasis[J].Diabetes, 2011, 60 (12) :3110-3120.

Relative Articles

[1]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[2]	Cheng ZHOU, Ran JIA, Jingjing WEI, Chenlu ZHAO, Dongfang SHANG, Wenxia ZHAO. Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2592-2595. doi: 10.3969/j.issn.1001-5256.2022.11.031
[3]	Yao ChengZi, Liu ZiZhen, Feng Gong, He Na, Mi Man. Risk factors for childhood nonalcoholic fatty liver disease and related prevention and management strategies[J]. Journal of Clinical Hepatology, 2020, 36(7): 1623-1626. doi: 10.3969/j.issn.1001-5256.2020.07.038
[4]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[5]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[6]	Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
[7]	Huang ZhiPeng, Jiang JianJia, Huang ZiCheng, Guo GuiYuan, Zhou APei, Liu XiaoQiang. Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area[J]. Journal of Clinical Hepatology, 2019, 35(5): 1061-1064. doi: 10.3969/j.issn.1001-5256.2019.05.025
[8]	Liu HongJin, Bao ChunMei, Bai WenLin, Li YinYin, Rong GuangHua, Lu YinYing, Chen Yan, Liu Ze, Cheng JiaMin, Ceng Zhen. Risk factors for infectious complications in primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1033-1037. doi: 10.3969/j.issn.1001-5256.2018.05.021
[9]	Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
[10]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[11]	Liu ZhengFang, Huang Wei, Li Qin. A risk factors analysis of acute-on-chronic liver failure complicated by spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2017, 33(4): 719-722. doi: 10.3969/j.issn.1001-5256.2017.04.024
[12]	Shi XinXing, Zhang YanQiong, Zhu Peng, Yan GuoHua, Zhang ZhangJiang, Wang YuMing. Prognostic risk factors in patients with hepatitis B virus- related acute- on- chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(4): 700-705. doi: 10.3969/j.issn.1001-5256.2016.04.018
[13]	Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
[14]	Yin TianSheng, Yi YaYang, Mao XiXian, Li DeWei. Meta-analysis of risk factors for posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1009-1014. doi: 10.3969/j.issn.1001-5256.2014.10.009
[15]	Chen YongFang, Wu ZhanJun. Pathogenesis and risk factors of cholesterol gallstones in patients with non- alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 952-955. doi: 10.3969/j.issn.1001-5256.2013.12.021
[16]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[17]	Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155.
[18]	Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
[19]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.

Supplements(0)

Cited By

Cited by

Periodical cited type(72)

1.	俞晓琦，张欣欣. 乙型肝炎病毒基因整合对功能性治愈的影响. 临床肝胆病杂志. 2025(01): 24-29 . 本站查看
2.	高娜，高志良. 慢性乙型肝炎功能性治愈离完全治愈还有多远？. 临床肝胆病杂志. 2025(01): 15-23 . 本站查看
3.	王怡恺，吴凤萍，刘晨瑞，郝苗，吕莎莎，张苗苗，党双锁，张欣. Mindin蛋白在经聚乙二醇干扰素α-2b治疗的慢性乙型肝炎中的动态变化及意义. 临床肝胆病杂志. 2024(01): 52-57 . 本站查看
4.	刘义思，任姗，郑素军，陈新月. 乙型肝炎疫苗——从预防到治疗. 临床肝胆病杂志. 2024(05): 1021-1025 . 本站查看
5.	蔡晓娟，汪美华，毛莉萍，缪幼菡，姚超，朱晓红. 恩替卡韦序贯联合聚乙二醇干扰素α-2b治疗低水平HBsAg阳性CHB患者疗效观察. 中西医结合肝病杂志. 2024(07): 587-591 .
6.	刘伟伟，史晓玉，王乐，徐琳娟. 恩替卡韦联合前列地尔治疗慢性乙型肝炎并发肝硬化腹水的效果分析. 中国实用医刊. 2024(12): 76-79 .
7.	朱豫萌，李国涛. HBV感染者HBV-DNA载量与血小板参数、炎性因子的关系探讨. 黑龙江医学. 2024(16): 1923-1925+1928 .
8.	宫雪莲，王鹏雁，李卫，田昊，张艳，孙英华，陈锡莲. 聚乙二醇干扰素α-2b治疗低HBeAg水平慢性乙型肝炎安全性及疗效预测因素. 国际医药卫生导报. 2024(16): 2771-2776 .
9.	木唤，许丹青，刘春云，刘立. 低HBsAg水平乙型肝炎患者使用干扰素治疗期间HBsAg与TSH的关系. 重庆医学. 2024(18): 2826-2829 .
10.	何谱，刘文宗. 抗病毒治疗慢性乙型肝炎患者发生低病毒血症的危险因素. 肝脏. 2024(09): 1105-1108 .
11.	李思泽，李小科，杜宏波，郑世豪，邹翔云，杨俞铖，叶永安. 慢性乙型肝炎中医证型及证素分布规律研究. 中西医结合肝病杂志. 2024(10): 875-878 .
12.	刘迪，王赵琛，翟晓梅. HIV治愈研究的伦理思考：价值与挑战. 医学与哲学. 2024(23): 10-15 .
13.	中国抗癌协会肿瘤临床研究管理学专业委员会，中国医师协会感染科医师分会，中国抗癌协会乳腺肿瘤整合康复专业委员会，中国医师协会外科医师分会乳腺外科专家工作组，国家肿瘤质控中心乳腺癌专家委员会，重庆市医师协会感染科医师分会，重庆市临床医学研究联合会. 乳腺癌患者化疗期间乙型肝炎病毒及丙型肝炎病毒再激活预防管理中国专家共识(2024版). 中华内分泌外科杂志. 2024(06): 751-760 .
14.	刘璐，孙明瑜. 乙型肝炎病毒相关性肾炎中西医诊疗进展. 中西医结合肝病杂志. 2023(01): 82-85 .
15.	王春艳，纪冬，陈艳，周光德，董政，王建军，陈国凤，杨永平. 慢性乙型肝炎患者经恩替卡韦治疗后获得显著组织学应答的影响因素及列线图模型构建. 解放军医学杂志. 2023(02): 143-150 .
16.	任艳，卞丹丹，梁晨，蒋莹莹，王扬，赵景，陈煜，段钟平，陈新月，郑素军. 血清鞘脂联合定量HBsAg对核苷（酸）类似物经治慢性乙型肝炎患者加用聚乙二醇干扰素α后HBsAg阴转的预测价值. 转化医学杂志. 2023(01): 15-21 .
17.	章申琰，沈忠良，张继明. 乙型肝炎核心相关抗原的分子基础与临床应用. 微生物与感染. 2023(01): 35-45 .
18.	邓雯，蒋婷婷，毕潇月，杨柳，林妍洁，张璐，李明慧. 干扰素治疗慢性乙型肝炎研究进展. 中国肝脏病杂志(电子版). 2023(02): 1-6 .
19.	李宽，宁会彬，靳慧鸣，彭真，尚佳. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者血清HBsAg清除率的效果分析. 临床肝胆病杂志. 2023(08): 1819-1824 . 本站查看
20.	胡义亭，赵娜，白万军，邱博，吴茵，宋浩静，张建，董占军. 基于医疗机构的治疗慢性乙型肝炎的核苷（酸）类似物的卫生技术评估. 中国药事. 2023(09): 1033-1046 .
21.	谭子跃. 干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响. 医学信息. 2023(20): 137-140 .
22.	贺潇瑾，龙云铸，周娟，李丹，周青，袁婷，卿玲，黄莎，陈芝慧，谭英征. 血清乙型肝炎病毒RNA监测聚乙二醇干扰素治疗核苷(酸)类似物经治低病毒载量慢性乙型肝炎患者疗效. 临床军医杂志. 2023(10): 1091-1095 .
23.	南然，席奇，刘永刚，宋春荣. 恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎肝衰竭的临床效果. 检验医学与临床. 2023(21): 3105-3108+3113 .
24.	吴宝灵，徐龙，余海滨，徐贞秋，吴敏，张伟，范声春，李艳艳，李金明. 血清HBsAg、HBV RNA水平对慢性乙型肝炎患者核苷(酸)类药物治疗停药预测的价值. 实用临床医学. 2023(05): 1-4 .
25.	王佳露，席德扬，颜学兵，季芳，李春杨. 聚乙二醇干扰素α-2b治疗HBeAg阴性慢性乙型肝炎患者实现HBsAg清除的预测因素及列线图构建. 临床肝胆病杂志. 2023(12): 2809-2816 . 本站查看
26.	潘微微，宋琦睿，连江山. 慢性乙型肝炎实现临床治愈的必要性及新方案探索. 临床内科杂志. 2023(12): 807-810 .
27.	陈芝慧，谭英征，龙云铸. 趋化因子配体13在常见感染性病原体感染中的表达及意义. 新发传染病电子杂志. 2023(05): 80-84 .
28.	邹磊，王大伟，施翠芬，王磊，王琪，杨国亚，支星，桑达文. 慢性乙型肝炎长期核苷(酸)类似物治疗过程中HBV储存库的变化规律研究. 中国现代药物应用. 2023(24): 82-85 .
29.	黄慧琴，谷斌，张春梅，侯小兰，宁峰，贺鹏志，李璐，卢恒剑. 核苷(酸)类似物经治CHB患者联合聚乙二醇干扰α-2b治疗的临床研究. 医学信息. 2022(01): 155-157 .
30.	陈圆圆，陈川铁，陈军. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎导致严重贫血2例. 中国热带医学. 2022(02): 186-190 .
31.	姚伟. 不同免疫检验方法检测乙型肝炎病毒感染血清学标志物的临床价值研究. 系统医学. 2022(02): 57-60 .
32.	刘影，徐汉辰，王磊. 中医药对慢性乙型肝炎免疫调节作用概述. 上海中医药杂志. 2022(05): 93-97 .
33.	王晓红，沈爱春，王丽净. 恩替卡韦联合扶正化瘀胶囊治疗乙肝肝硬化对患者血清纤维化标志物的影响. 当代医学. 2022(14): 95-97 .
34.	吴凤萍，鲁瑞，刘怡欣，李梅，石娟娟，党双锁. 基于GEO数据库筛选慢性乙型病毒性肝炎患者对干扰素α治疗无应答相关的关键免疫基因和通路. 西安交通大学学报(医学版). 2022(03): 407-412 .
35.	刘炜炜，马陈斌，田芝奥，顾征太，吴霞. 肝宁片联合替诺福韦酯对甲胎蛋白升高慢性乙型病毒性肝炎患者血清AFP水平、APRI评分及肝纤维化程度的影响. 中西医结合肝病杂志. 2022(06): 516-519 .
36.	黄燕，张琼月，罗二平，赵卫峰，甘建和. HBsAg>3000 IU/mL慢性乙型肝炎非优势人群临床治愈2例报告. 临床肝胆病杂志. 2022(07): 1608-1611 . 本站查看
37.	陈诚，杨青青，陈邦涛，陈伟庆. 血清IL-17A通过抑制DEL-1参与慢性乙型肝炎发病的机制研究. 中国免疫学杂志. 2022(12): 1494-1498 .
38.	孙华宝，李美琦，赖启南，斯志娟，漆童丰，王淑梅. 血清HBV RNA定量检测在慢性乙肝患者抗病毒治疗中临床研究. 实验与检验医学. 2022(03): 306-309 .
39.	鲁瑞，党双锁，刘怡欣，王怡恺，刘晨瑞，李亚萍，吴凤萍，李梅. 富马酸替诺福韦酯治疗的慢性乙型肝炎患者3年血清HBV DNA和HBsAg的动态变化. 临床肝胆病杂志. 2022(10): 2224-2229 . 本站查看
40.	程齐齐，杨丽霞，蔡天盼，王亮，孙俊，梁佳圆，刘丽萍，甘厦，阮宁杭，葛善飞. 核苷（酸）类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志. 2022(12): 2716-2722 . 本站查看
41.	朱雪丽，林照坤，王丽芸. HBV pgRNA表达水平与慢性乙型肝炎患者核（苷）酸类似物治疗反应性的相关性. 实用医学杂志. 2022(20): 2585-2589+2596 .
42.	钟抒苡，刘寿荣. 抗病毒治疗后HBV准种动态变化及不同感染下的演变过程. 中西医结合肝病杂志. 2022(11): 1053-1056 .
43.	彭月，周喜汉，于莹莹，柏鸽，黎明吉. 免疫细胞在肝纤维化发生发展及治疗中的作用机制. 山东医药. 2021(04): 101-104 .
44.	叶永安. 慢性乙型肝炎的治疗现状与中医药“免疫孵育”策略的实践. 中西医结合肝病杂志. 2021(02): 97-101 .
45.	王浩楠，梁士兵，姚晓玲，来保勇，文天元，苏宁. 复方甘草酸苷注射液改善慢性乙型肝炎肝损伤疗效和安全性的系统评价与Meta分析. 中国中药杂志. 2021(03): 694-702 .
46.	吴凤萍，李妙羡，王怡恺，鲁瑞，刘怡欣，党双锁. 恩替卡韦单药治疗慢性乙型肝炎患者5年HBsAg与HBV DNA的动态变化. 临床肝胆病杂志. 2021(05): 1047-1052 . 本站查看
47.	鲁凤民，封波，郑素军，蒋素贞，杨瑞锋，福军亮，纪冬，党双锁，鲁晓擘，陈红松，陈新月，任红，高志良，南月敏，徐小元，俊奇，张文宏，庄辉. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状. 临床肝胆病杂志. 2021(06): 1268-1274 . 本站查看
48.	李广平，张红心，张蕾，周鹏翔，王亚囡. 透明质酸、Ⅳ型胶原、APRI及纤维蛋白原-4对乙型肝炎后肝纤维化的诊断价值. 临床和实验医学杂志. 2021(13): 1385-1388 .
49.	段金伟，张鹏，张婧，曾婉嘉，鲁凤民. 慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义. 临床肝胆病杂志. 2021(07): 1682-1685 . 本站查看
50.	朱志强，姜太一，吴昊. 男男性行为者HIV感染队列中新发HBV感染的特点及影响因素. 中国艾滋病性病. 2021(08): 859-861 .
51.	张瑜，路青华，曹海芳，张生荣. 聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响. 医学信息. 2021(17): 114-116 .
52.	王嘉悦，李天驹，付豪，秦波. 聚乙二醇干扰素治疗慢性乙型病毒性肝炎早期HBsAg快速下降的临床及免疫学特征研究. 中国感染与化疗杂志. 2021(05): 557-565 .
53.	吴凤萍，鲁瑞，刘怡欣，王怡恺，田燕，张欣，贾晓黎，党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析. 实用肝脏病杂志. 2021(05): 677-680 .
54.	蒋丹容. 恩替卡韦分散片治疗慢性乙型肝炎的临床效果及对肝功能的影响. 临床合理用药杂志. 2021(32): 58-60 .
55.	安子英，丁洋. 慢性乙型肝炎病毒感染的临床治愈策略. 中国实用内科杂志. 2021(11): 941-945 .
56.	段飞云，陈晓明，胡汝源，陈建萍，杨桂芝，李瑞忠，马婉聪. 2017—2020年大理州健康人群乙型肝炎血清学时空相关性分析. 国际病毒学杂志. 2021(05): 412-415 .
57.	齐海峰，金峰花，崔玉顺，李香玉. 基于健康管理模式的健康教育对155例慢性乙型肝炎患者生命质量的影响. 延边大学医学学报. 2021(03): 201-203 .
58.	翁奉武，郭丽颖，李秋伟，李力，赵立聪，孙小雪，尹美君，贾建伟. 外周血淋巴细胞亚群在慢性HBV感染过程中表达的变化分析. 临床肝胆病杂志. 2020(01): 65-69 . 本站查看
59.	张晨，尚立. 阿德福韦酯联合重组人干扰素α_2b注射液治疗乙型病毒性肝炎患者的疗效. 临床医学研究与实践. 2020(05): 46-48 .
60.	李璟，杜虹. 唐都医院传染科2013—2019年收治的肝病患者的流行病学分析. 临床医学研究与实践. 2020(10): 1-2+5 .
61.	刘小菊，张政. 从HBV特异性免疫细胞角度谈慢性乙型肝炎功能性治愈. 临床肝胆病杂志. 2020(05): 977-979 . 本站查看
62.	王颖，赵奎，秦建忠. HBV cccDNA、HBsAg、HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值. 临床肝胆病杂志. 2020(05): 1008-1013 . 本站查看
63.	高晓红，成妮，曹姣姣. 聚乙二醇干扰素α-2b治疗乙型肝炎肝硬化实现临床治愈1例报告. 临床肝胆病杂志. 2020(06): 1347-1348 . 本站查看
64.	蒋莹莹，郑素军. 核苷(酸)类似物治疗慢性乙型肝炎发生HBe Ag血清学转换的预测标志物. 临床肝胆病杂志. 2020(06): 1358-1361 . 本站查看
65.	闫秀丽，商嘉玮，苏式兵，胡义扬，张辉. 慢性乙型病毒性肝炎肝胆湿热证和肝郁脾虚证患者尿液中microRNAs的表达研究. 上海中医药杂志. 2020(07): 39-46+51 .
66.	陈华仙，韦嘉. HBeAg阴性慢性乙型肝炎的诊治进展. 临床肝胆病杂志. 2020(07): 1612-1614 . 本站查看
67.	邱效东，常亚丽，周亚伟，赵珺，桑坦，翟丽亚，陈昀. 伊布替尼致乙肝病毒再激活1例报告并文献复习. 山东医药. 2020(26): 57-60 .
68.	陈希，崔毅峙，王通. 基于茎环引物探针法定量检测乙型肝炎病毒miR-3的方法学建立. 中国病理生理杂志. 2020(09): 1721-1728 .
69.	马路园，赵彩彦. 从2019《新指南》谈慢性乙型病毒性肝炎抗病毒治疗进展. 河北医科大学学报. 2020(10): 1117-1120+1125 .
70.	王欣茹，肖丽，耿爱文，咸建春. 聚乙二醇干扰素治疗慢性乙型肝炎诱发血栓性血小板减少性紫癜1例报告. 临床肝胆病杂志. 2020(11): 2534-2536 . 本站查看
71.	陈诗琦，毛日成，张继明. 乙型肝炎病毒核心蛋白变构调节剂的研究进展. 微生物与感染. 2020(05): 322-330 .
72.	王晶晶，纪冬，陈国凤. 慢性乙型肝炎的治愈现状. 传染病信息. 2020(06): 566-570 .

Other cited types(34)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3017) PDF downloads(621)

Roles of GCK mRNA and GLUT2 in abnormal glucose metabolism among patients with severe chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2013.08.014